Evidence map›Paper›PMID 40621806›Full record

ReviewCancer medicine2025

Tumor-Infiltrating Lymphocytes in Breast and Female Genital Tract Cancers: Overlooked Potential and Unexplored Frontiers.

Kristijan Skok, Umberto Maccio, Spencer D Martin, Konstantin Bräutigam

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Kristijan SkokDiagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria.ORCID https://orcid.org/0000-0002-3027-8164
Umberto MaccioDepartment of Pathology and Molecular Pathology, University Hospital of Zurich, Zurich, Switzerland.
Spencer D MartinDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Konstantin BräutigamCentre for Evolution and Cancer, Institute of Cancer Research, London, UK.

Funding

Javna Agencija za Raziskovalno Dejavnost RS I0-0029Javna Agencija za Raziskovalno Dejavnost RS P3-0036Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung P500PM_217647/1
6 · The paper itself

Abstract

backgroundThe growing success of cancer immunotherapies has led to significant advances in oncology. However, despite these promising developments, cancer-related mortality remains high for common cancer types such as breast and lower female genital tract cancers.

methodHere, we synthesize recent findings on the prognostic relevance of tumor-infiltrating lymphocytes (TILs) in breast, endometrial, tubo-ovarian, and vulvar cancer. Our analysis covers the relationship between TIL counts and density, immune cell subtype combinations, immunotherapy approaches, and patient outcomes.

resultsHigh TIL infiltration, especially CD8

conclusionsTIL-based therapies have shown potential in personalized immunotherapy, particularly in recurrent, refractory ovarian cancer. Limited research on rarer gynecologic tumors hinders broader clinical applications.

Indexed as

Breast NeoplasmsGenital Neoplasms, FemaleLymphocytes, Tumor-InfiltratingFemaleHumansImmunotherapyPrognosisTumor Microenvironmentbreast cancerendometrial cancerfallopian tubeimmunotherapyovarian cancerreviewtumor‐infiltrating lymphocytes (TILs)tumor microenvironment (TME)vulvar cancer

Identifiers

PMID40621806
PMCPMC12230770

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.